- Research article
- Open Access
- Open Peer Review
A lupane-triterpene isolated from Combretum leprosum Mart. fruit extracts that interferes with the intracellular development of Leishmania (L.) amazonensis in vitro
© Teles et al. 2015
- Received: 16 June 2014
- Accepted: 20 May 2015
- Published: 6 June 2015
3beta,6beta,16beta-trihydroxylup-20(29)-ene is a lupane triterpene isolated from Combretum leprosum fruit. The lupane group has been extensively used in studies on anticancer effects; however, its possible activity against protozoa parasites is yet poorly known. The high toxicity of the compounds currently used in leishmaniasis chemotherapy stimulates the investigation of new molecules and drug targets for antileishmanial therapy.
The activity of 3beta,6beta,16beta-trihydroxylup-20(29)-ene was evaluated against Leishmania (L.) amazonensis by determining the cytotoxicity of the compound on murine peritoneal macrophages, as well as its effects on parasite survival inside host cells. To evaluate the effect of this compound on intracellular amastigotes, cultures of infected macrophages were treated for 24, 48 and 96 h and the percentage of infected macrophages and the number of intracellular parasites was scored using light microscopy.
Lupane showed significant activity against the intracellular amastigotes of L. (L.) amazonensis. The treatment with 109 μM for 96 h reduced in 80 % the survival index of parasites in BALB/c peritoneal macrophages. At this concentration, the triterpene caused no cytotoxic effects against mouse peritoneal macrophages. Ultrastructural analyses of L. (L.) amazonensis intracellular amastigotes showed that lupane induced some morphological changes in parasites, such as cytosolic vacuolization, lipid body formation and mitochondrial swelling. Bioinformatic analyses through molecular docking suggest that this lupane has high-affinity binding with DNA topoisomerase.
Taken together, our results have showed that the lupane triterpene from C. leprosum interferes with L. (L.) amazonensis amastigote replication and survival inside vertebrate host cells and bioinformatics analyses strongly indicate that this molecule may be a potential inhibitor of topoisomerase IB. Moreover, this study opens major prospects for the development of novel chemotherapeutic agents with leishmanicidal activity.
- Leishmania (L.) amazonensis
- Combretum leprosum
- Antileishmanial activity
Leishmaniasis is a neglected disease caused by several protozoan species of the genus Leishmania, an intracellular parasite that infect cells of the mononuclear phagocyte system. These protozoan parasites cause a number of important human diseases, including cutaneous, mucocutaneous and visceral leishmaniasis. The parasites are transmitted by sandflies of the genera Phlebotomus (old World) and Lutzomyia (New World) by inoculation of infective metacyclic promastigote forms during the blood meal. These infective metacyclic forms are internalized by host macrophages and differentiate into amastigote forms that are able to proliferate within the phagolysosomes of mammalian macrophages, thus being responsible for the maintenance and propagation of the infection .
The first-line compounds for the treatment of Leishmaniasis consists of pentavalent antimonials, sodium stibogluconate and meglumine antimoniate. The second line of drugs includes pentamidine and amphotericin B (also formulated as liposomes). Most of these drugs present high toxicity, several side effects, and require long-term management, complicating the conclusion of treatment. Discovered in the mid-1980s, miltefosine is orally active antileishmanial drug, approved in India in 2002 for the therapy of leishmaniasis; but its efficacy on the treatment of American cutaneous leishmaniasis has been shown to be variable depending on the causative species, moreover this drug is associated with therapeutic complications [2, 3].
Plant extracts have been traditionally used in the treatment of protozoan diseases; in addition, a number of alternative compounds with antileishmanial activity have been described, including chalcones, alkaloids, triterpenes, acetogenins [4–9]. Despite of the activity of several compounds in experimental murine leishmaniasis models, the development of a single drug or formulation has been hindered by factors such as visceral and cutaneous sites of infection, intrinsic variation of the Leishmania species known to infect humans, and, finally, cytotoxicity .
Combretum leprosum Mart., a member of the family Combretaceae, contains many compounds, such as triterpenes, flavonoids, stilbenes, phenantrenes, lignans, alkaloids [11, 12]. In a phytochemical study of C. leprosum roots and leaves, Facundo et al.  have isolated arjunolic and mollic acids and 3β,6β,16β-trihydroxylup-20(29)-ene, and found out that the arjunolic acid has potent anti-inflammatory, anti-nociceptive and anticholinesterasic properties [12, 13]. Previous studies from our laboratory have revealed that 3β,6β,16β-triidroxilup-20(29)-ene obtained from C. leprosum fruit extracts exhibited anti-leishmanial activity against L. (L.) amazonensis promastigotes, with an IC50 of 3.3 μg/mL . L. (L.) amazonensis is a species transmitted mainly in the Amazon region and causes diffuse cutaneous leishmaniasis (DCL) . This species can be associated with localized and benign cutaneous lesions and can also cause mucocutaneous leishmaniasis . Diffuse cutaneous leishmaniasis (DCL) is a form of cutaneous leishmaniasis that begins as localized and non-ulcerated papules or nodules that then spread to several parts of the body [15–17]. Although rare, DCL is a disease that does not respond to treatments in satisfactory manner .
There is an urgent need of new, effective and safe drugs for a better control of leishmaniasis. Therefore, new targets need to be set in order to pursue the development of a newer generation of anti-protozoan drugs, and amongst potential molecular targets, DNA topoisomerases warrant special attention. DNA topoisomerases IB are ubiquitous enzymes responsible for relaxing superhelical tension in DNA by forming a transient covalent nick in one strand of the DNA duplex . DNA topoisomerase inhibitors represent a main class of anti-cancer drugs with an increasing number of compounds which are nowadays in clinical use. These enzymes have been also proposed as potential targets for the development of anti-protozoan drugs, such as pathogenic trypanosomatids, including Leishmania spp. [20–22]. In addition, the significant differences in homology between leishmania DNA topoisomerase IB and the human form provide a new lead in the study of the structural determinants that can be targeted .
The present study investigated the effects of 3β,6β,16β-triidroxilup-20(29)-ene on the development of L. (L.) amazonensis amastigotes within peritoneal mouse macrophages. Furthermore, the potential affinity between leishmania DNA topoisomerase IB and 3β,6β,16β-triidroxilup-20(29)-ene was also studied using bioinformatics molecular docking analyses.
Mice and parasites
Female BALB/c mice aged eight to ten weeks were obtained from the breeding stock of Research Institute for Tropical Diseases - IPEPATRO, Porto Velho, RO, Brazil. Promastigotes of Leishmania (Leishmania) amazonensis PH8 strain (IFLA/BR/67/PH8) were axenically cultured at 23 °C in RPMI 1640, supplemented with 10 % heat-inactivated fetal bovine serum (FBS), 20 mM Hepes (N-2-hydroxyetrylpiperazine-N’-2-ethanesulfonic acid), and 50 μg/mL of gentamycin. On the 5th day of culture (stationary phase of growth), promastigotes were harvested and washed with RPMI by centrifugation at 1000 × g for 15 min. Parasite pellets were then resuspended in culture medium and used for infection of peritoneal macrophages in vitro.
Toxicity on macrophages
With the purpose of evaluating the cytotoxicity of lupane against host cells, thyoglicholate-elicited peritoneal macrophages were incubated at different concentrations (6,5 – 218 μM) of triterpene for 24 h, 48 h and 96 h, at 37 °C, under an atmosphere of 5 % CO2. The samples were dissolved in ethanol. Up to 1 % (v/v), ethanol had no effect on macrophage viability and parasite growth. The viability of macrophages was determined using a CellTiter 96 Aqueous Non-Radioactive cell proliferation assay (Promega), following the manufacturer’s instructions. Three independent experiments were performed in duplicate.
Macrophage infection and parasite survival
The effects of C. leprosum lupane on parasite replication and survival in host macrophages were evaluated by plating BALB/c thyoglycholate-elicited peritoneal macrophages into coverslips placed into 24-well culture plates and infecting them with L. (L.) amazonensis promastigotes at a ratio of 10:1 for 18 h at 34 °C in an atmosphere of 5 % CO2. Free parasites were removed by washing the macrophages thoroughly before adding the drugs. The infected cultures were treated with 109 μM lupane. A control for the solvent used to dissolve lupane (ethanol) was also included. The cultures were incubated at 34 °C, 5 % CO2, and analyzed at 24, 48 and 96 h post-treatment . Infected macrophages incubated without drugs were used as control, whereas Glucantime® was used as a control drug at 546,5 μM. In order to estimate the survival index, the coverslips were stained with May Grünwald-Giemsa  and 100 macrophages were scored by light microscopy, either as infected or non-infected. Likewise, these preparations were assessed for the number of parasites inside the macrophages. The survival index was determined by multiplying the number of infected cells by the mean number of amastigotes per cell. The results were used to establish a proportion in relation to the control and hence express the result as a percentage.
Transmission electron microscopy
Control and treated infected-macrophages were washed with Phosphate Buffer Saline (PBS) and fixed with 2.5 % glutaraldehyde in 0.1 M cacodilate buffer (pH 7.2). These cells were detached by gently scraping immediately after the addition of glutaraldehyde and then incubated at room temperature for 1 h. Cells were post-fixed in a solution containing 1 % OsO4 and 0.8 % potassium ferricyanide, for 1 h, dehydrated in a graded series of acetone, and embedded in Epon resin. Ultrathin sections were stained with uranyl acetate and lead citrate and images were obtained using a Zeiss 900 transmission electron microscope.
The PARMODEL web server  has been used to model the DNA topoisomerase IB (EC 126.96.36.199) from Leishmania braziliensis in apo form (gene name: LbrM20_V2.3020). The atypical heterodimeric DNA topoisomerase IB from Leishmania is composed of a large subunit containing the phylogenetically conserved “core” domain and a small subunit harboring the C-terminal region with the tyrosine residue common in the active site. This study was carried out on the model of this conserved core that consisted of 430 amino acids. Therefore, we have used the atomic coordinates of topoisomerase IB from Leishmania donovani (PDB access code: 2b9s) , which presents 93.25 % identity with the DNA topoisomerase IB (EC 188.8.131.52) from Leishmania braziliensis (LbTOPO). PARMODEL is a parallelized version of the MODELLER web server . All water molecules and DNA atomic coordinates were removed from the topoisomerase IB structure (PDB access code: 2b9s) so that the template structure was prepared. The modeling procedure begins from the alignment of the sequence to be modeled (target) with a related three-dimensional structure (template). The alignment being considered is usually the input to the program while, on the other hand, the output is a three-dimensional model for the target sequence containing all main-chain and side-chain non-hydrogen atoms. In the modeling process, a total of 100 models were generated and the final model was selected based on objective function of the MODELLER.
Docking applications can be classified as a function of their search algorithm, which is defined by a set of rules and parameters applied to predict the conformations. When considering the flexibility of the ligand and/or the receptor, docking algorithms can be classified into two major groups: rigid-body and flexible docking. We have applied the flexible docking protocol available in the program MolDock , wherein the flexibility of the ligand is simulated. MolDock is an implementation of a heuristic search algorithm that joins together differential evolution and a cavity calculation algorithm. In addition, MolDock evaluates the best poses applying a docking scoring function, which is used to piecewise linear potential (PLP), previously implemented in the program GEMDOCK . As for MolDock, the docking scoring function is extended with an additional term, taking hydrogen bond directionality into account. Furthermore, a re-ranking procedure is also applied in order to augment docking accuracy.
The present docking simulation was based on a previously described protocol applied to Leishmania donovani DNA topoisomerase crystal structure (PDB access code: 2b9s). In this protocol the core domain of topoisomerase structure has been used as a target for the docking simulations. A site known to have important residues (Arg-314, Lys-352 and Arg-410) can only be exposed by removing the DNA molecule. The structure of LbTOPO was modeled without DNA or water molecules, as described above.
Lupeol was previously proposed as an important pharmacophore for topoisomerase I inhibition . As regards what has been described, we have employed the lupeol core to access the ZINC database  and then build a small-molecule database. A total of 100 molecules were retrieved and used to build this database, which is available for download at http://zinc.docking.org/ . Molecular docking simulations were carried out employing a validated protocol previously described .
Results were presented as mean ± S.D. and were statistically evaluated by Two-Way ANOVA Repeated Measures, followed by the Tukey test at significance level of ≤ 0.05.
All animals were handled in strict accordance with good animal practice as defined by the relevant national and/or local animal welfare bodies, and all animal work was approved by the Animal Use Ethics Committee of IPEPATRO (registration number 2008/4).
Evaluation of macrophage viability
Lupane effects on L. (L.) amazonensis survival in the host cell
In the lupane-treated macrophages, infection was reduced when compared to the control and glucantime-treated macrophages, which showed parasites multiplying progressively (Fig. 3b). At 24 h post-treatment, the mean number of intracellular amastigotes in Glucantime® and lupane-treated macrophages was lower than that in the control cells (33 % and 15 % respectively). Nevertheless, after 96 h, macrophages treated with Glucantime® were seen to harbor a number of parasites comparable to the control cells, indicating that this treatment did not interfere with parasite replication. In turn, at this time point, macrophages treated with lupane have harbored a significantly lower number of parasites (F = 8.6; p = 0.0002) as compared to control (Fig. 3b). These results indicate that the C. leprosum isolated compound inhibited parasite growth inside the macrophages.
Molecular docking of lupane and DNA topoisomerase
The analysis of the protein-ligand interaction has revealed the participation of intermolecular hydrophobic contacts and hydrogen bonds. All hydroxyl groups present in the lupane participate in intermolecular hydrogen bonds. The main chain carbonyl oxygen and amide nitrogen of Arg 190 participate in hydrogen bonds with a hydroxyl group of lupane. The side chain of Arg 190 makes a strong intramolecular hydrogen bond with the side chain of Asp 353 in the LbTOPO structure, which provides further stability to the structure, working as an anchor for the hydroxyl group of lupane. All the side chains of residues Lys 319, Thr 326 and Lys 352 participate in intermolecular hydrogen bonds; overall, 5 interactions of this type are observed in the LbTOPO-lupane complex. Lys 352 has been previously identified as an important residue of intermolecular interaction in the structure of topoisomerase IB from L. (L.) donovani . Likewise, Arg 314 has been proposed as an important spot for intermolecular interaction. In the present structure, the side chain of Arg 314 is about 4 Å away from the lupane, i.e., the limit for Van der Waals contacts. The analysis of electrostatic molecular surface indicates the presence of a hydrophilic patch in the binding pocket, which favors polar interactions with the hydroxyl groups (Fig. 5b).
The antileishmanial activity of the lupane triterpene isolated from fruits of Combretum leprosum was first described in a previous study, confirming that this plant has a potential antiprotozoal action . Both the crude extract and the isolated lupane have potent toxic activity against L. (L.) amazonensis promastigotes. The present work revealed that the 3β,6β,16β-trihydroxylup-20(29)-ene is also effective in eliminating the L. (L.) amazonensis intracellular amastigotes. At the concentration of 109 μM, no cytotoxicity of lupane has been detected on mouse peritoneal macrophages during the experimental period. However, as expected, concentrations above 218 μM showed a significant level of toxicity in the macrophages.
In a related study, a betulinic aldehyde isolated from Doliocarpus dentatus (Aubl.) showed in vitro activity against L. (L.)amazonensis amastigotes, but also showed toxicity against peritoneal macrophages . There is few published data concerning the action of lupanes against protozoa parasites [34, 35], and most studies focused the antitumoral activity of these substances [36–39].
Sarek et al.  and Kommera et al.  demonstrated that minor structural changes on compounds derived from lupane interfere with the in vitro cytotoxic activity against tumor cell lines, suggesting a structure-activity relationship. Our group showed that structural modifications in natural 3β,6β,16β-trihydroxylup-20(29)-ene, such as the presence of acetyl groups at 3β and 16β abolished its leishmanicidal activity. On the other hand, the replacement of hydroxyl groups by carbonyl groups did not significantly affect its leishmanicidal activity . A recent study from our laboratory compared the lupane leishmanicidal activity against different Leihsmania species and demonstrated that this triterpene also had a potent anti-proliferative effect against the promastigotes of L. braziliensis and L. guyanensis (unpublished results).
The 3β,6β,16β-trihydroxylup-20(29)-ene concentration adopted in this study was sufficient to reduce the rate of infected macrophages and the number of intracellular amastigotes from 24 h-post treatment onwards. The effect of lupane was time-dependent, reaching a survival index of 16 at 96 h-post treatment. Furthermore, lupane showed a higher inhibitory activity on the growth of leishmania parasites as compared to that of Glucantime®.
Maes et al.  have analyzed the action of six triterpenes saponins isolated from a Vietnamese plant Maesa balansae Mez. (Myrsinaceae) against L. donovani and L. infantum. The triterpene saponins from M. balansae inhibit the intracellular growth of L. infantum amastigotes and the subcutaneous administration of 0.4 mg/kg of the substance in BALB/c mice infected with L. donovani was able to reduce the parasite load by 95 %. Additionally, the triterpene saponin named Maesabalide III had the most potent antileishmanicidal activity in vivo towards L. donovani-infected hamsters, leading to a 99.8 % reduction of the parasite load after a seven-day treatment .
Glucantime®, which is one of the drugs currently used in the treatment of leishmaniasis, was unable to reduce infection over the time analysed. Infected cells treated with Glucantime® showed a survival index of 47.2 at 24 h, but this index was seen to increase to 98.8 at 96 h. Since the 40s’, pentavalent antimonials are the drugs of choice for the treatment of leishmaniasis; however, the mechanism of action of two of them - meglumine antimoniate (Glucantime®) and sodium stibogluconate - is not well known. Several studies suggest that pentavalent antimony may be a pro-drug and that it can be converted into trivalent antimony inside the infected cell possibly interfering in the process of glycolysis of the parasite. Moreover, it could affect enzyme inhibition and thereby lead to the depletion of intracellular ATP levels [42, 43]. Unfortunately, these drugs cause severe side effects and the treatment is usually extensive.
In this work, the parasite ultrastructure was affected by the treatment with lupane, since cells exhibited loss of cytosolic content, which culminated in cell lysis. The nucleus of the treated leishmania presented a less compact chromatin and it was observed mitochondrial swelling as previously reported after the use of topoisomerase I inhibitors in Trypanosoma cruzi . Zuma et al.  showed that Camptothecin and rebeccamycin, eukaryotic topoisomerase I inhibitors, were effective in arrest of T. cruzi replication and the ultrastructural alterations, such as the unpacking of nuclear heterochromatin and mitochondrial swelling were observed.
Chowdhury et al.  showed that dihydrobetulinic acid - a derivative of betulinic acid - has antileishmanial activity against both L. donovani promastigotes and amastigotes forms, and that it inhibits DNA topoisomerases I and II. This pentacyclic triterpenoid causes damage in nuclear DNA and induces apoptosis in L. donovani parasites. The same authors have recently demonstrated that three synthetic derivatives of betulin (disuccinylbetulin, diglutaryldihydrobetulin, and disuccinyldihydrobetulin) reduced replication of the intracellular L. donovani amastigotes, in addition to inhibiting the relaxation activity of the enzyme type IB topoisomerase [Leishmania donovani topoisomerase I (LdTOP1LS)] of the parasite .
The analysis of the intermolecular interaction between 3β,6β,16β-trihydroxylup-20(29)-ene and LbTOPO indicates a perfect coupling and a strong binding affinity. The strong antileshmanial activity interfering with amastigote survival, and the high virtual affinity binding with LbTPOPO suggest that the 3β,6β,16β-trihydroxylup-20(29)-ene may be a potential inhibitor of L. (L.) amazonensis topoisomerase IB. The in silico data is necessary to confirm this inhibiton, but results indicate that the used bioinformatic analyses were able to identify potential new antileishmanial drugs.
Type IB topoisomerases are enzymes essential to cell life which form a covalent bond with the 3’ end of broken DNA strands. Leishmania type I DNA topoisomerase differ from their homologues in other eukaryotic cells. The DNA topoisomerases I from mammalian hosts are monomeric enzymes, whereas the trypanosomatid type I DNA topoisomerases are heterodimeric [47, 48]. Moreover, this enzyme has a dual localization in trypanosomatids: in the nucleus, associated with genomic DNA, and in the kinetoplast, associated with kDNA [49, 50]. These differences make such enzyme a potential target for chemotherapeutic intervention in diseases caused by trypanosomatids parasites.
A big step was taken forward in the development of drugs over the last years, allowing for the treatment of a broad spectrum of pathologies. Unfortunately, diseases caused by protozoan parasites, such as trypanosomes, leishmania and plasmodia are not included in research and development programs from the pharmaceutical sector [51, 52], resulting in a challenging scenario for the development of new drugs in face of these orphan diseases.
Finally, the results of this study have revealed that a natural triterpene, a lupane isolated from C. leprosum, has antileishmanial activity against L. (L.) amazonensis intracellular amastigotes and, by bioinformatic analysis, interacts with type IB parasite DNA topoisomerase. This compound represents a new source of molecules for the development of novel antiprotozoal agent and may be a potential candidate for the treatment of leishmaniasis.
This work was supported by CNPQ (National Council for Scientific and Technological Development) and FAPERJ.
- Naderer T, McConville MJ. Intracellular growth and pathogenesis of Leishmania parasites. Essays Biochem. 2011;51:81–95.View ArticlePubMedGoogle Scholar
- Singh N, Kumar M, Singh RK. Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med. 2012;5:485–97.View ArticlePubMedGoogle Scholar
- Machado PR, Penna G. Miltefosine and cutaneous leishmaniasis. Curr Opin Infect Dis. 2012;25:141–4.View ArticlePubMedGoogle Scholar
- Zhai L, Chen M, Blom J, Theander TG, Christensen SB, Kharazmi A. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother. 1999;43:793–803.View ArticlePubMedGoogle Scholar
- Grandic SR, Fourneau C, Laurens A, Bories C, Hocquemiller R, Loiseau PM. In vitro antileishmanial activity of acetogenins from Annonaceae. Biomed Pharmacother. 2004;58:388–92.View ArticleGoogle Scholar
- Maes L, Berghe DV, Germonprez N, Quirijnem L, Cos P. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesabalansae against visceral Leishmania species. Antimicrob Agents Chemother. 2004;48:130–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Silva FMA, Koolen HHF, Lima JPS, Santos DMF, Silva-Jardim I, Souza ADL, et al. Leishmanicidal activity of fractions rich in aporphine alkaloids from Amazonian Unonopsis species. Rev Bras Farmacogn. 2012;22:1368–71.View ArticleGoogle Scholar
- Paes-Goncalves HP, Facundo VA, Santos DMF, Silva AGC, Ballico LJ, Lima DKS, et al. The leishmanicidal activity of a cyclopentenedione derivative isolated from the roots of a native Amazonian pepper (Piper carniconnectivum C. DC, Piperaceae). Rev Bras Farmacogn. 2012;22:1018–23.View ArticleGoogle Scholar
- Santos AO, Izumi E, Ueda-Nakamura T, Dias-Filho BP, Veiga-Júnior VF, Nakamura CV. Antileishmanial activity of diterpeneacids in copaibaoil. Mem Inst Oswaldo Cruz. 2013;108:59–64.View ArticlePubMedPubMed CentralGoogle Scholar
- Croft SL, Karin S, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res. 2006;123:399–410.PubMedGoogle Scholar
- Facundo VA, Andrade CHS, Silveira ER, Braz-Filho R, Hufford C. Triterpenes and flavonoids from Combretum leprosum. Phytochemistry. 1993;32:411–5.View ArticleGoogle Scholar
- Pietrovski EF, Rosa KA, Facundo VA, Rios K, Marques MC, Santos AR. Antinociceptive properties of the ethanolic extract and of the triterpene 3beta,6beta,16beta-trihidroxilup-20(29)-ene obtained from the flowers of Combretum leprosum in mice. Pharmacol Biochem Behav. 2006;83:90–9.View ArticlePubMedGoogle Scholar
- Facundo VA, Rios KA, Medeiros CM, Militão JSLT, Miranda ALP, Epifânio RA, et al. Arjunolic acid in the ethanolic extract of Combretum leprosum root and its use as a potential multi-functional phytomedicine and drug for neurodegenerative disorders: anti-inflammatory and anticholinesterasic activities. J Braz Chem Soc. 2005;16:1309–12.View ArticleGoogle Scholar
- Teles CBG, Moreira LS, Silva AA, Facundo VA, Zuliani JP, Stábeli RG, et al. Activity of the Lupane isolated from Combretum leprosum against Leishmania amazonensis promastigotes. J Braz Chem Soc. 2011;22:936–42.View ArticleGoogle Scholar
- Silveira FT, Lainson R, Corbett CEP. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil. A Review Mem Inst Oswaldo Cruz. 2004;99:239–51.View ArticlePubMedGoogle Scholar
- Barral A, Pedral Sampaio D, Grimaldi Jr G, Momem HMC, Mahon-Pratt D, Jesus A, et al. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am J Trop Med Hyg. 1991;44:536–46.PubMedGoogle Scholar
- Morrison B, Mendoza I, Delgado D, Reyes Jaimes O, Aranzazu N, Paniz-Mondolfi AE. Diffuse (anergic) cutaneou leishmaniasis responding to amphotericin B. Clin Exp Dermatol. 2009;35:116–9.View ArticleGoogle Scholar
- Zerpa O, Ulrich M, Blanco B, Polegre M, Ávila A, Matos N, et al. Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Brit J Dermatol. 2007;156:1328–35.View ArticleGoogle Scholar
- Davies DR, Mushtaq A, Interthal H, Champoux JJ, Hol WG. The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA. J Mol Biol. 2006;357:1202–10.View ArticlePubMedGoogle Scholar
- Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci U S A. 1995;92:3726–30.View ArticlePubMedPubMed CentralGoogle Scholar
- Balaña-Fouce R, Alvarez-Velilla R, Fernández-Prada C, García-Estrada C, Reguera RM. Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery. Int J Parasitol Drugs Drug Resist. 2014;4:326–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Motta MCM. Kinetoplast as a potential chemotherapy target of trypanosomatids. Curr Pharm Des. 2008;14:847–54.View ArticlePubMedGoogle Scholar
- Silva-Jardim I, Horta MF, Ramalho-Pinto FJ. The Leishmania chagasi proteasome: role in promastigotes growth and amastigotes survival within murine macrophages. Acta Trop. 2004;91:121–30.View ArticlePubMedGoogle Scholar
- Giaimis J, Lombard Y, Makaya-Kumba M, Fonteneau P, Poindron P. A new and simple method for studying the binding and ingestion steps in the phagocytosis of yeasts. J Immunol Methods. 1992;154:185–93.View ArticlePubMedGoogle Scholar
- Uchoa HB, Jorge GE, Da Silveira NJF, Camera JC, Canduri F, De Azevedo WF. Parmodel: a web server for automated comparative modeling of proteins. Biochem Biophys Res Commun. 2004;325:1481–6.View ArticlePubMedGoogle Scholar
- Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779–815.View ArticlePubMedGoogle Scholar
- Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem. 2006;49:3315–21.View ArticlePubMedGoogle Scholar
- Yang JM, Chen CC. GEMDOCK: a generic evolutionary method for molecular docking. Proteins. 2004;55:288–304.View ArticlePubMedGoogle Scholar
- Wada S, Iida A, Tanaka R. Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity. J Nat Prod. 2001;64:1545–7.View ArticlePubMedGoogle Scholar
- Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005;45:177–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Timmers LFS, Pauli I, Caceres RA, De Azevedo Jr WF. Drug-Binding Databases. Curr Drug Targets. 2008;9:1092–9.View ArticlePubMedGoogle Scholar
- Misra P, Khaliq T, Dixit A, SenGupta S, Samant M, Kumari S, et al. Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J Antimicrob Chemother. 2008;62:998–1002.View ArticlePubMedGoogle Scholar
- Sauvain M, Kunesch N, Poisson J, Gantier J-C, Gayral P, Dedet J-P. Isolation of leishmanicidal triterpenes and lignans from Amazoniam liana Doliocarpus dentatus (Dellineaceae). Phytother Res. 1996;10:1–4.View ArticleGoogle Scholar
- Gnoatto SC, DallaVechia L, Lencina CL, Dassonville-Klimpt A, Da Nascimento S, Mossalayi D, et al. Synthesis and preliminary evaluation of newursolic and oleanolic acids derivatives as antileishmanial agents. J Enzyme Inhib Med Chem. 2008;23:604–10.View ArticlePubMedGoogle Scholar
- Silva-Filho AA, Resende DO, Fukui MJ, Santos FF, Pauletti PM, Cunha WR, et al. In vitro antileishmanial, antiplasmodial and cytotoxic activities of phenolics and triterpenoids from Baccharis dracunculifolia D. C. (Asteraceae). Fitoterapia. 2009;80:478–82.View ArticlePubMedGoogle Scholar
- Kommera H, Kaluderović GN, Kalbitz J, Dräger B, Paschke R. Small structural changes of pentacyclic lupane type triterpenoid derivatives lead to significant differences in their anticancer properties. Eur J Med Chem. 2010;45:3346–53.View ArticlePubMedGoogle Scholar
- Lee DY, Seo KH, Lee DS, Kim YC, Chung IS, Kim GW, et al. Bioactive 3,4-seco-Triterpenoids from the Fruits of Acanthopanax sessiliflorus. J Nat Prod. 2012;75:1138–44.View ArticlePubMedGoogle Scholar
- Laszczyk MN. Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 2009;75:1549–60.View ArticlePubMedGoogle Scholar
- Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell GA, et al. Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med. 1995;1:1046–51.View ArticlePubMedGoogle Scholar
- Sarek J, Klinot J, Dzubák P, Klinotová E, Nosková V, Krecek V, et al. New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships. J Med Chem. 2003;46:5402–15.View ArticlePubMedGoogle Scholar
- Maes L, Germonprez N, Quirignen L, Puyvelde LV, Cos P, Berghe DV. Comparative activities of the triterpenesaponin Maesabalide III and Liposomal amphotericin B (AmBisome) against Leishmania donovani in Hamsters. Antimicrob Agents Chemother. 2004;48:2056–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Berman JD, Waddell D, Hanson BD. Biochemical Mechanisms of the Antileishmanial Activity- of Sodium Stibogluconate. Antimicrob Agents Chemother. 1985;27:916–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Frézard F, Martins PS, Barbosa MC, Pimenta AM, Ferreira WA, de Melo JE, et al. New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate. J Inorg Biochem. 2008;102:656–65.View ArticlePubMedGoogle Scholar
- Zuma AA, Cavalcanti DP, Maia MC, De Souza W, Motta MCM. Effect of topoisomerase inhibitors and DNA-binding drugs on the cell proliferation and ultrastructure of Trypanosoma cruzi. Int J Antimicrob Agents. 2011;37:449–56.View ArticlePubMedGoogle Scholar
- Chowdhury AR, Mandal S, Goswami A, Ghosh M, Mandal L, Chakraborty D, et al. Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy. Mol Med. 2003;9:26–36.PubMedPubMed CentralGoogle Scholar
- Chowdhury S, Mukherjee T, Sengupta S, Chowdhury SR, Mukhopadhyay S, Majumder HK. Novel betulin derivatives as antileishmanial agents with mode of action targeting type IB DNA topoisomerase. Mol Pharmacol. 2011;80:694–703.View ArticlePubMedGoogle Scholar
- Villa H, Otero Marcos AR, Reguera RM, Balaña-Fouce R, García-Estrada C, Pérez-Pertejo Y, et al. A novel active DNA topoisomerase I in Leishmania donovani. J Biol Chem. 2003;278:3521–6.View ArticlePubMedGoogle Scholar
- Reguera RM, Redondo CM, Gutierrez de Prado R, Pérez-Pertejo Y, Balaña-Fouce R. DNA topoisomerase I fromparasitic protozoa: a potential target for chemotherapy. Biochim Biophys Acta. 2006;1759:117–31.View ArticlePubMedGoogle Scholar
- Bodley AL, Chakraborty AK, Xie S, Burri C, Shapiro TA. An unusual type IB topoisomerase from African trypanosomes. Proc Natl Acad Sci U S A. 2003;100:7539–44.View ArticlePubMedPubMed CentralGoogle Scholar
- Das BB, Sen N, Ganguly A, Majumder HK. Reconstitution and functional characterization of the unusual bi-subunit type I DNA topoisomerase from Leishmania donovani. FEBS Lett. 2004;565:81–8.View ArticlePubMedGoogle Scholar
- De Azevedo Jr WF. Targets for Development of Drugs Against Orphan Diseases. Curr Drug Targets. 2007;8:387.View ArticleGoogle Scholar
- De Azevedo Jr WF, Soares MBP. Selection of targets for drug development against protozoan parasites. Curr Drug Targets. 2009;10:193–201.View ArticleGoogle Scholar